Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Treasury Shares (2016 - 2025)

Vanda Pharmaceuticals' Treasury Shares history spans 16 years, with the latest figure at $3.5 million for Q4 2025.

  • For Q4 2025, Treasury Shares rose 31.19% year-over-year to $3.5 million; the TTM value through Dec 2025 reached $3.5 million, up 31.19%, while the annual FY2025 figure was $3.5 million, 31.19% up from the prior year.
  • Treasury Shares for Q4 2025 was $3.5 million at Vanda Pharmaceuticals, roughly flat from $3.5 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $3.5 million in Q2 2025 and bottomed at $1.8 million in Q4 2021.
  • The 5-year median for Treasury Shares is $2.0 million (2022), against an average of $2.4 million.
  • The largest annual shift saw Treasury Shares fell 2.33% in 2023 before it soared 42.05% in 2024.
  • A 5-year view of Treasury Shares shows it stood at $1.8 million in 2021, then grew by 8.55% to $1.9 million in 2022, then decreased by 0.53% to $1.9 million in 2023, then surged by 39.09% to $2.7 million in 2024, then soared by 31.19% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Treasury Shares are $3.5 million (Q4 2025), $3.5 million (Q3 2025), and $3.5 million (Q2 2025).